Standout Papers

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a random... 2008 2026 2014 2020 993
  1. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008)
    Edward S. Kim, Vera Hirsh et al. The Lancet
  2. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial (2017)
    Dong‐Wan Kim, Marcello Tiseo et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 8 from Science/Nature 69 standout
Sub-graph 1 of 18

Citing Papers

Lung cancer
2021 Standout
Evaluating eligibility criteria of oncology trials using real-world data and AI
2021 StandoutNature

Works of Edward S. Kim being referenced

Modernizing Eligibility Criteria for Molecularly Driven Trials
2015
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
2012

Author Peers

Author Last Decade Papers Cites
Edward S. Kim 5186 5109 1863 2856 211 9.5k
Tarek Mekhail 6781 5661 1793 2932 168 10.3k
Daniel D. Karp 3760 4694 1571 2856 213 9.2k
Robert Pirker 5304 7281 1813 3752 248 11.4k
Christopher G. Azzoli 7341 5873 1417 2351 154 10.0k
Martin J. Edelman 4218 4479 920 1927 296 8.5k
Philip Bonomi 4349 4803 961 2075 240 7.8k
Frank V. Fossella 9030 8709 1060 2581 196 12.9k
George R. Blumenschein 4981 6894 2383 2671 324 11.7k
Maciej Krzakowski 6332 7455 1576 2156 243 11.1k
Sumithra J. Mandrekar 3267 4171 1336 1730 208 8.9k

All Works

Loading papers...

Rankless by CCL
2026